Eliem Therapeutics Outlines Interim Data From Early-Stage Depressive Study – Eliem Therapeutics (NASDAQ:ELYM)

 Eliem Therapeutics Inc ELYM announced interim results from its ongoing Section 1 demo of ETX-155 for key depressive disorder…
Change Your Business

 Eliem Therapeutics Inc ELYM announced interim results from its ongoing Section 1 demo of ETX-155 for key depressive disorder…
US infectious conditions company BARDA is encouraging to fund the demo with a grant truly worth up to $seventy two.5mln.…
WhatsApp us